Dementia deaths in the UK have reached a record high of 81,096 annually, surpassing fatalities from heart disease and stroke, according to new figures analyzed by the Alzheimer's Society. This represents a more than 15 percent increase since 2016, when dementia first became the nation's leading cause of death.

Last year's toll was nearly 20,000 higher than deaths attributed to heart disease and more than double the number of deaths from stroke and lung cancer combined. The figures for 2025 showed a 5.5 percent increase compared to the previous year, which recorded 76,894 deaths.

Dementia, an umbrella term for progressive brain disorders such as Alzheimer's disease, disproportionately affects women. In 2025, approximately 16.2 percent of all female deaths in the UK listed dementia as a cause, compared to 8.9 percent of male deaths.

The majority of these deaths, 72,272, were recorded in England and Wales. In Scotland, dementia has overtaken heart disease as the primary cause of mortality for the first time, with 6,685 deaths. Northern Ireland recorded 2,139 dementia-related deaths.

Geographically, Surrey Heath in England had the highest proportion of dementia deaths, with one in five fatalities (20 percent) attributed to the disease. East Devon and Tunbridge Wells followed with 18.2 percent and 17.8 percent, respectively.

Experts highlight the growing challenge dementia poses to an aging society. Professor Dame Carol Brayne noted that as people live longer and survive other major diseases, dementia will remain a significant concern, emphasizing the need for risk reduction and exploration of effective treatments.

Michelle Dyson, chief executive of Alzheimer's Society, described the figures as a "stark warning" and called for the government to give dementia the same priority as other major health conditions like cancer. She urged for a commitment to ensure no patient waits longer than 18 weeks from referral to diagnosis, care plan, and treatment.

Concerns are also mounting about the UK's ability to provide timely diagnoses and access to potentially life-extending treatments. The UK reportedly has fewer MRI, CT, and PET scanners per capita compared to 16 other developed nations, with access unevenly distributed.

Recent advancements in treatment offer some hope. New drugs like lecanemab and donanemab have shown potential in slowing cognitive decline in early Alzheimer's, though they have faced hurdles in NHS adoption due to cost-benefit analyses. Additionally, a new twice-yearly injection, diranersen, which targets tau proteins linked to brain cell death, has shown promise in halving the rate of cognitive decline in phase two trials.

The Daily Mail's Dementia Carers Together Appeal, in partnership with Alzheimer's Society and Mail Force charity, is raising funds for six-week courses designed to provide crucial emotional and practical support to friends and relatives caring for individuals with dementia.